Search

for
Search:

Glossary Live Attenuated Vaccine

weakened pathogen used to stimulate immune response without causing disease

A Live Attenuated Vaccine (LAV) is a type of vaccine created by reducing the virulence of a pathogen, but still keeping it viable (or "live"). This means the pathogen is weakened so it can't cause disease in healthy individuals, but it can still stimulate a strong immune response. Examples include the measles, mumps, and rubella (MMR) vaccine.

Related Terms

Research

5 / 1000+ results

research Clinical Quiz No. 2

January 2016 in “Elsevier eBooks”

This article discusses dermatophycosis, a fungal infection affecting various animals, and outlines its transmission, diagnosis, treatment, and prevention methods, but reports no new research findings.

research Rhodococcus equi: Clinical Manifestations, Virulence, and Immunity

119 citations , October 2011 in “Journal of Veterinary Internal Medicine”

This review discusses the clinical manifestations and immune response to Rhodococcus equi infection in foals but reports no new clinical results.

research Therapeutic applications and pharmacoeconomics of microneedle technology

24 citations , June 2018 in “Expert Review of Pharmacoeconomics & Outcomes Research”

This review discusses the potential of microneedle arrays for drug delivery and in the cosmetic market, but reports no new clinical results; factors for commercial therapeutic use are explored.

research Inverse micellar sugar glass (IMSG) nanoparticles for transfollicular vaccination

38 citations , March 2015 in “Journal of controlled release”

This study found that transfollicular delivery using surfactant-based nanoparticles significantly enhanced antigen stability and immune response compared to other delivery methods, especially when combined with an adjuvant.

research Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine

33 citations , June 2021 in “Dermatologic Therapy”

This study reports that a patient with subacute cutaneous lupus erythematosus experienced disease exacerbation after the first dose of the BNT162b2 mRNA COVID-19 vaccine, but tolerated the second dose without adverse reactions.

View more "live attenuated vaccine" in research →

Learn

— no results

Try a deeper search in learn →

Community Join

— no results

Try a deeper search in community →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →